Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ: VNDA · Real-Time Price · USD
4.315
-0.015 (-0.35%)
At close: May 28, 2025, 4:00 PM
4.310
-0.005 (-0.12%)
After-hours: May 28, 2025, 4:37 PM EDT
Vanda Pharmaceuticals Revenue
Vanda Pharmaceuticals had revenue of $50.04M in the quarter ending March 31, 2025, with 5.43% growth. This brings the company's revenue in the last twelve months to $201.35M, up 13.37% year-over-year. In the year 2024, Vanda Pharmaceuticals had annual revenue of $198.77M with 3.18% growth.
Revenue (ttm)
$201.35M
Revenue Growth
+13.37%
P/S Ratio
1.25
Revenue / Employee
$547,149
Employees
368
Market Cap
254.30M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 198.77M | 6.13M | 3.18% |
Dec 31, 2023 | 192.64M | -61.74M | -24.27% |
Dec 31, 2022 | 254.38M | -14.30M | -5.32% |
Dec 31, 2021 | 268.68M | 20.51M | 8.27% |
Dec 31, 2020 | 248.17M | 20.98M | 9.23% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
VNDA News
- 1 day ago - Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting - PRNewsWire
- 12 days ago - Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025 - PRNewsWire
- 20 days ago - Vanda Pharmaceuticals Inc. (VNDA) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 21 days ago - Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results - PRNewsWire
- 23 days ago - Vanda Announces Bysanti™ NDA Filing; FDA Decision Expected in Early 2026 - PRNewsWire
- 26 days ago - Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025 - PRNewsWire
- 5 weeks ago - FDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and Falsely Blame Commissioner Makary and the reductions in force at FDA - PRNewsWire
- 7 weeks ago - Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting - PRNewsWire